ProfileGDS5678 / 1446321_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 10% 9% 9% 9% 9% 10% 11% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.2573310
GSM967853U87-EV human glioblastoma xenograft - Control 22.232629
GSM967854U87-EV human glioblastoma xenograft - Control 32.235139
GSM967855U87-EV human glioblastoma xenograft - Control 42.179759
GSM967856U87-EV human glioblastoma xenograft - Control 52.175559
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.2873210
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.3007311
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.210059
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.198339
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.220639
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.217239
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.204349
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.22639
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.222679